nmol/L (superfused), but those <100 ,um dilated only at the C alcitonin gene-related peptide (CGRP) is one of the most potent endogenous vasodilators of peripheral resistance vessels in humans.' In the coronary circulation, CGRP-immunoreactive nerve fibers are located in extramural coronary arteries of dogs,2 and both large conduit vessels and arterioles have CGRP receptors in humans and guinea pigS.3 CGRP is detected in picomolar concentrations in the circulation of normal mammals.45 Moreover, CGRP is released from guinea pig hearts during myocardial ischemia,6 and the plasma concentration of CGRP increases during acute myocardial infarction in humans.7 In addition, a recent study indicates that CGRP activates ATP-sensitive K' channels,8 which are important for the physiological or pathophysiological regulation of coronary circulation.9-"1 Therefore, it is important to determine if CGRP is involved in the regulatory mechanisms of coronary circulation in physiological or pathophysiological conditions. Exogenous CGRP causes potent dilation of epicardial conduit vessels in humans.2'13 However, the effect of CGRP on coronary resistance vessels is still unclear. Several studies have evaluated this issue by coronary blood flow or coronary sinus oxygen saturation and have reported conflicting results. 13-'5 Accordingly, the purpose of this study was to clarify the effects of CGRP on coronary arterial microvessels and to elucidate whether CGRP modulates the tone of coronary arterial microvessels during acute myocardial ischemia.
In the present study, we used direct visualization of coronary microcirculation because recent studies have shown that coronary microvessels of different sizes respond differently to various vasoactive substances or stimuli.16-'9 To simulate the effect of endogenous CGRP on the coronary microcirculation, we examined the effects of exogenous CGRP applied by two different routes, ie, intracoronary infusion and superfusion. There were several reasons for this approach. First, CGRP appears to have its major effect by a local release from nerves located on the outside of vessels. Second, the arterial endothelium has neutral endopeptidase20 that can cleave CGRP. 21 Third, periarterial nerve stimulation or capsaicin treatment releases many substances other than CGRP.
Methods

General Preparation
Forty-two small mongrel dogs of either sex, weighing 4 to 9 kg, were premedicated with ketamine (10 mg/kg IM) and anesthetized with an intravenous injection of a-chloralose (60 mg/kg; Wako Pure Chemical Industries, Osaka, Japan). Ventilation was controlled with a Harvard respirator (model NSH-34RH; Harvard Apparatus, South Natick, Mass). To measure aortic pressure, a catheter was introduced into the aortic root via the right carotid artery and connected to a strain-gauge pressure transducer (model MPU 0.5; Toyo Sokki, Tokyo, Japan). A left thoracotomy was performed in the fifth intercostal space, and the heart was suspended in a pericardial cradle. Aortic pressure was maintained at control level by a snare placed around the descending thoracic aorta, and a balloon catheter was placed in the inferior vena cava. Heart rate was kept constant at 140 beats per minute by left atrial pacing after sinus node suppression with a local injection of 10% buffered formaldehyde (0.3 to 0.5 mL). A polyvinyl catheter was inserted into the left atrium through the appendage for the injection of fluorescent dye. For the measurements of left ventricular pressure and dP/dt, a 16-gauge Teflon tube was inserted into the left ventricle through the apex and connected to a strain-gauge pressure transducer (model MPU 0.5; Toyo Sokki). When intracoronary infusion of drugs was required, a tiny catheter (outer diameter, 0.67 mm, Surflo; Terumo, Tokyo, Japan) was retrogradely inserted into the left anterior descending coronary artery (LAD). To prevent damage to nerve fibers supplying the observed microvessels, the catheter was inserted by using direct puncture22 at a point distal to the branching point of the observed vessels. When LAD occlusion was required, a snare was placed around its proximal portion using an atraumatic needle. To prevent damage to nerve fibers around the LAD, the LAD was not dissected, and the snare was placed to surround it and the adjacent myocardium. The distal pressure of the LAD was measured with a tiny catheter inserted into the distal LAD or its branch. The cardiac surface was kept moist during the experiments by superfusing warm (37°C) modified Krebs' solution containing (in mmol/L): NaCl 118.2, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25.0, calcium disodium EDTA 0.026, and glucose 5.5 (pH 7.40) at a rate of 1 mL/min. To reduce excessive cardiac movement, two 24-gauge stainless-steel needles were inserted horizontally (5 to 10 mm apart) into the midmyocardium of the left ventricle. Both ends of each needle were fixed to a needle holder held with coil springs. This apparatus allowed the heart to move perpendicularly but limited excessive horizontal movement to hold the area of interest in the microscopic field of view. Blood flow velocity of the LAD was measured at the proximal portion using a small suction-cup Doppler probe23 connected to a pulsed Doppler flowmeter (model 100; Triton Technology Inc, San Diego, Calif). Lead II ECG, aortic and ventricular pressures, left ventricular dP/dt, distal coronary pressure, and mean and phasic coronary blood flow velocities were simultaneously recorded on a rectigraph (model 8K; San-Ei Sokki, Tokyo).
Microscope System
The microscope system equipped with a floating objective has been described in detail elsewhere.22,2425 Briefly, the floating objective consists of a pair of convex lenses aligned on a common optical axis, which transmits the real image of the epimyocardium of a beating left ventricle to a fixed position without any change in magnification. The convex lens facing the heart can move in unison with the up-and-down motion of the cardiac surface without directly touching it. The image on the front focus of this lens is transmitted to the back focus of the second convex lens with parallel light. Consequently, a change in distance between these two lenses does not affect the position or magnification of the transmitted real image. Therefore, it is possible to continuously observe the coronary microcirculation in beating hearts by observing the transmitted real image with a standard microscope. For transillumination of the microvessels, a light-conducting glass fiber (diameter, 0.6 mm) mounted in the lumen of a 20-gauge stainless-steel needle was inserted into the midmyocardium of the left ventricle with a micromanipulator. The needle was connected to a needle holder that allows the tip of the needle to move up and down in unison with the cardiac motion.
Microvascular Diameter Measurement
Images of coronary microvessels were obtained with epiilluminated fluorescence microangiography or transillumination of the epimyocardium. In the protocol of normal perfusion pressure, fluorescein isothiocyanate dextran (MW, 154 200; Sigma Chemical Co, St Louis, Mo) was injected as a 4-to 10-mg bolus (20 mg/mL in saline) into the left atrium as a contrast medium. The left ventricular surface was epiilluminated by incident light from a mercury lamp (model HBO-100EW/2; Nikon Inc, Tokyo, Japan). Microvascular fluorescent images were recorded using a silicon-intensified tube videocamera (model C1000-12; Hamamatsu Photonics, Hamamatsu, Japan) and videocassette recorder (model AG-7350; Panasonic, Tokyo). In the protocol of LAD occlusion, transillumination of the microvessels with a xenon arc lamp or epi-illuminated fluorescence microangiography was performed, and the obtained images were recorded with the same system described above. Even during the LAD occlusion, microvessels were slowly but clearly visualized by the fluorescent dye through the collaterals. In the end-diastolic phase, arteriolar diameters were measured on a high-resolution monitor (model C1846-01; Hamamatsu Photonics) using a video manipulator (model C2117; Hamamatsu Photonics). The microscope objective used for this study was a Leitz model PL-fl (x 10; numerical aperture, 0.30).
Drugs
Papaverine hydrochloride and sodium nitroprusside were purchased from Wako Chemicals, Osaka, Japan. CGRP (human CGRP I) and CGRP [human CGRP-(8-37)]26,27 were purchased from Peptide Institute, Osaka, Japan. When CGRP was administered by intracoronary infusion, CGRP was dissolved in modified Krebs' solution and infused into the LAD at a rate of 0.3 mUmin with a microinfusion pump (model STC-521; Terumo Inc, Tokyo). Papaverine hydrochloride was dissolved in saline (10 mg/mL), and 4 mg was injected as a bolus into the LAD. When CGRP, CGRP , and sodium nitroprusside were superfused, they were dissolved in modified Krebs' solution at a concentration 10-fold higher than the final concentration exposed to the cardiac surface and then superfused from the side port of the modified Krebs' superfusion line at a rate of 0.1 mL/min with a microinfusion pump (model STC-521; Terumo Inc). Preliminary studies showed that intracoronary infusion of the modified Krebs' solution at a rate of 0.3 mb'min did not affect the resting diameters of arterial microvessels compared with the values before infusion (small [diameter <100 ,um], In protocol 1, the effect of CGRP on coronary arterial microvessels was assessed. CGRP was applied by intracoronary infusion or superfusion. In seven dogs, control hemodynamics and microvascular images were obtained, and then CGRP was infused into the LAD for 5 minutes at dosages of 0.05, 0.5, 5.0, and 50 pmol/kg per minute in a cumulative fashion. These four doses were estimated to achieve intracoronary concentrations of 0.025 to 56 nmol/L based on the assumed coronary blood flow of 0.8 mL/min per gram of left ventricle. Thereafter, 4 mg papaverine hydrochloride was injected into the LAD to determine the vasodilator reserve. At the end of each dose of CGRP and just after papaverine infusion, hemodynamics and microvascular images were obtained. In the other seven dogs, control hemodynamics and microvascular images were obtained, and then CGRP (0.03, 0.3, 3.0, and 30 nmol/L) was superfused over the left ventricular surface for 5 minutes in a cumulative fashion. Then, 100 ,umol/L sodium nitroprusside was superfused for 5 minutes to determine the vasodilator reserve. At the end of each dose of CGRP and nitroprusside, hemodynamics and microvascular images were obtained. Arterial blood gases and pH in all protocols were maintained within the normal range throughout the experiment (Table 1) . Systemic hemodynamics were maintained at control level during the study in each protocol except for the highest dose of intracoronary CGRP and papaverine infusion in protocol 1 (Tables 2  and 3 ). The highest dose of CGRP infusion decreased diastolic aortic pressure but did not significantly change systolic and mean aortic pressures. Diastolic and mean aortic pressures decreased with the intracoronary infusion of papaverine. Intracoronary infusion of CGRP did not alter left ventricular dP/dt at any dose. Mean control diameters of coronary arterial microvessels in each protocol are shown in Table 4 . Effect of CGRP on Coronary Arterial Microvessels CGRP administered by intracoronary infusion or superfusion showed a similar tendency to preferentially dilate the microvessels more than approximately 100 ,um in diameter (Figs 1 and 2) . Therefore, coronary arterial microvessels were divided into two groups according to their control diameters (small: internal diameter <100 ,um; large: internal diameter .100 ,um) for comparison of different size vessels (Fig  3) . Control diameters of the two vessel groups did not differ for protocols 1 and 2 (Table 4 ). When CGRP was infused into the coronary artery, CGRP at the dosage of 0.05 pmol/kg per minute had no significant effect on any size vessels (Figs 1 and 3A) . At 0.5 and 5.0 pmol/kg per minute, CGRP dilated only the large-vessel group (2.2+0.6% and 5.8±1.3%, respectively; P<.05) ( Fig  3A) . The highest dose of CGRP dilated both vessel groups but with greater dilation in the large-vessel group (small: 5.4±1.8%; large: 11.8±1.3%; P<.05) ( Fig  3A) . Only the highest dose of CGRP increased the coronary flow velocity ( Table 2 ). Papaverine markedly dilated both vessel groups (Fig 3A) and markedly increased the coronary flow velocity (Table 2) . When CGRP was superfused, the lowest dose of CGRP failed to dilate either vessel group (Figs 2 and 3B ). For the other three doses, the large-vessel group dilated dose dependently (5.2±1.4%, 7.5±1.5%, and 11.9±2.1% at each dose; P<.05) (Fig 3B) . The small-vessel group dilated only at the highest dose of CGRP (7.4±2.0%, P<.05). Nitroprusside markedly dilated both vessel groups (Fig 3B) . When the effect of CGRP on each vessel group was compared for intracoronary infusion and superfusion, no significant difference was observed at any dose. However, the small-vessel group tended to constrict at medium doses in the former and to dilate in the latter (Fig 3) . Also, in the superfusion group, the magnitude of dilation in the small-and large-vessel groups was significantly different only for the third dose, although there was similar dilation of the large-vessel groups in both protocols (Fig 3) .
Potency of CGRP(8-37) as a CGRP Antagonist in Coronary Microvessels
The diameters of the large-vessel group were not different from control during the superfusion of 100 and 300 nmol/L of CGRP(8-37) (-1.1±1.5% and -0.8±1.3%, respectively). Also, the diameters of the small-vessel group were not different from control during the superfusion of 300 nmol/L of CGRP (0.3±0.5%). The superfusion of 300 nmol/L of CGRP(8-37) completely abolished the dilation of the large-vessel group induced by the intracoronary infusion or superfusion of each dose of CGRP (Fig 4) . Also, CGRP failed to dilate the small-vessel group during the superfusion of 300 nmol/L of CGRP Table 3 . In both timed control and CGRP groups, mean aortic pressure was maintained at control level during the LAD occlusion and was not different for these two groups (Table 3) . Mean distal coronary pressure decreased to approximately 30 mm Hg during the LAD occlusion and was not different for these two groups (Table 3) . Percent change in diameter from control during the LAD occlusion is shown in Fig 5. In the timed control group, the diameters of the small-vessel group dilated, and those of the large-vessel group did not change with the LAD occlusion and were stable throughout the LAD occlusion in both vessel groups (Fig 5) . Also, in the CGRP(8-37)-treated group, the diameters of the small-vessel group dilated and those of the large-vessel group did not change with the LAD occlusion. The diameters of the small-and large-vessel groups were stable during the LAD occlusion and were not altered with the following superfusion of CGRP 
Discussion Main Findings
The present study demonstrated that CGRP caused potent dilation of arterial microvessels >100 ,um in diameter but had only a small effect on those approximately <100 ,um. Although CGRP microvessels were minimal. The cannula for CGRP infusion was retrogradely inserted at a site distal to the branching point of the observed vessels. Therefore, CGRP-containing nerves supplying the observed vessels were not damaged by this procedure. In the same preparation, Komaru et a122 examined the effect of the inserted cannula on the perfusion pressure of the observed vessels and showed that the cannula did not alter perfusion pressure. Because the snare for the LAD occlusion was placed around it with the use of an atraumatic needle that did not dissect it, damage to the nerves around the LAD appeared to be minimal. In the present study, two heart-stabilizing needles and a lightconducting needle were inserted into the midmyocardium. These needles may have some influence on the vasomotion of observed vessels. However, several investigators have suggested that the effect of inserted needles is of little importance.17,2829 Previous reports from our laboratory have demonstrated that microvascular reactivity to various agents or stimuli is well preserved in this preparation.9 19, 22, 24, 25 Also, in the present study, papaverine or nitroprusside markedly dilated coronary arterial microvessels. Dose of CGRP and Endogenous CGRP CGRP is detected in picomolar concentrations in the circulation of humans and rats,4-5 and dog extramural coronary arteries have CGRP-immunoreactive nerve fibers.2 In the present study, the lowest dose of CGRP mimicked the basal plasma level of CGRP. Ischemia induces a severalfold increase in CGRP outflow in isolated, perfused guinea pig heart.6 Also, in humans, plasma CGRP increases severalfold in acute myocardial infarction.7 Although the increase of plasma CGRP may be only severalfold in myocardial ischemia, the local concentration of CGRP in the coronary vascular wall may be much higher than the plasma level. Therefore, 
